Combination ATR and PARP Inhibitor (CAPRI) trial with AZD6738 and Olaparib in recurrent ovarian cancer

Brief description of study

This project studies combination AZD6738 and olaparib (Lymparza) to treat recurrent ovarian cancer. It will examine 1) the safety and tolerability of this drug combination and 2) the overall response rate (tumor strinkage rate) of this therapy. All study patients have recurrent ovarian cancer. None of the patients have standard medication options.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
recurrent ovarian cancer
Gender: Female

Updated on 09 Mar 2024. Study ID: 827744

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).